Clostridia Consortia Reverse Colitis via Tryptophan‑Driven Microbiome and Immune Modulation
Defined human Clostridia consortia 17‑mix and 11‑mix reverse established colitis in multiple murine IBD models. Beyond SCFA and IL‑10 pathways, these live biotherapeutic products suppress resident pathobionts and activate anti‑inflammatory AhR signaling via bacterial tryptophan metabolites, revealing IL‑10‑independent mechanisms of microbiome‑based therapy.